Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gut check: could your microbiome be key to obesity and diabetes?

NCT ID NCT07205913

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how gut bacteria are linked to obesity and type 2 diabetes in New Caledonia, where these conditions are very common. Researchers will collect blood, urine, and stool samples from 270 adults to analyze their gut microbes and related chemicals. The goal is to better understand these diseases in this population, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal how gut bacteria influence obesity and diabetes, pointing toward future dietary or probiotic interventions.
What could go wrong
This is an observational study, not a treatment trial. It will not directly improve health, and findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 270 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults living in New Caledonia who are obese with or without type 2 diabetes or healthy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 18 and 60 years. * Ability to understand and provide informed consent. * Ability and willingness to meet the required schedule and study interventions. * Willingness to share their community belonging * Benefit from a social security system. For obese and diabetic patients : * IMC ≥ 30 kg/m² with type 2 diabetes * Fasting plasma glucose (FPG) ≥7 mM (=1.26g/l) or * Patients with HbA1c ≥ 6.5% (48 mmol/mol) * All stages of albuminuria For obese patients without type 2 diabetes * IMC ≥ 30 kg/m² * Weight stable for at least 2 months * Patients with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) and an HbA1c \< 6.5 % * No treatment (diabetic or weight loss) * Match age (±5years), sex and self-reported community to the patients from the1 group. For control group : * BMI between 18.5-24.9 kg/m² * Match age (±5years), sex and self-reported community to the patients from the 1 and 2 groups. * Participants with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) and an HbA1c \< 6.5 % Exclusion Criteria: All participants : * Treatment that may alter gastrointestinal motor function, acidity, microbial population, or immunosuppressants * Altered anatomy of the esophagus, stomach, small intestine, or large intestine due to gastrointestinal surgery (except appendectomy or cholecystectomy) * Chronic or acute inflammatory bowel disease or infections * Abdominal or pelvic radiation therapy or abdominal cancer, colorectal cancer * Dysphagia, eosinophilic esophagitis, esophageal stricture, or other swallowing disorders * Organ transplantation and patients receiving immunosuppressive therapy * Severe renal failure and/or patients undergoing dialysis * Cardiovascular, endocrine, renal, or other chronic disease that may affect motility. * Preparation for colon cleansing within the last month * \< 3 bowel movements per week * Women who are pregnant or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.